Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing

Mutations in the serine/threonine kinase BRAF are found in more than 60% of melanomas. The most prevalent melanoma mutation is BRAF(V600E), which constitutively activates downstream MAPK signaling. Vemurafenib is a potent RAF kinase inhibitor with remarkable clinical activity in BRAF(V600E)-positive...

Full description

Saved in:
Bibliographic Details
Published in:Nat Commun
Main Authors: Salton, Maayan, Kasprzak, Wojciech K., Voss, Ty, Shapiro, Bruce A., Poulikakos, Poulikos I., Misteli, Tom
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4435825/
https://ncbi.nlm.nih.gov/pubmed/25971842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms8103
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items